REST EZ (RTEZ) 10-Q 14 Feb 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2022	Feb. 08, 2023
Document Information Line Items
Entity Registrant Name	REST EZ, INC.
Document Type	10-Q
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding		20,000,000
Amendment Flag	false
Entity Central Index Key	0001733861
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-256498
Entity Incorporation, State or Country Code	WY
Entity Tax Identification Number	82-4268982
Entity Address, Address Line One	1398 W. Mason Hollow Dr.
Entity Address, City or Town	Riverton
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84065
City Area Code	(801)
Local Phone Number	300-2542
Title of 12(b) Security	None
No Trading Symbol Flag	true
Security Exchange Name	NONE
Entity Interactive Data Current	Yes

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Current assets
Cash	$ 177	$ 431
Deposits	405,000	405,000
Inventory	2,550	2,550
Total current assets	407,727	407,981
Total assets	407,727	407,981
Current liabilities
Accounts payable	96	0
Income taxes payable	41,687	41,687
Loan from related party	129,279	118,450
Total current liabilities	171,062	160,137
Stockholders' equity
Common stock, $0.001 par value, 100,000,000 shares authorized, 20,000,000 shares issued and outstanding as of December 31, 2022 and March 31, 2022	20,000	20,000
Additional paid-in capital	118,962	111,291
Retained earnings	97,703	116,553
Total stockholders' equity	236,665	247,844
Total liabilities and stockholders' equity	$ 407,727	$ 407,981

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued	20,000,000	20,000,000
Common stock, shares outstanding	20,000,000	20,000,000
Common stock, shares authorized	100,000,000	100,000,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 0	$ 345,000	$ 0	$ 519,443
Cost of goods sold	0	165,000	0	269,050
Gross profit	0	180,000	0	250,393
Operating expenses:
General and administrative	2,061	9,875	11,179	23,785
Total operating expenses	2,061	9,875	11,179	23,785
Net Operating Income (loss)	(2,061)	170,125	(11,179)	226,608
Other income (expense):
Interest expense	(2,586)	(2,303)	(7,671)	(7,615)
Total other expense	(2,586)	(2,303)	(7,671)	(7,615)
Income (loss) before provision for income taxes	(4,647)	167,822	(18,850)	218,993
Provision for income taxes	0	0	0	0
Net income (loss)	$ (4,647)	$ 167,822	$ (18,850)	$ 218,993
Net income (loss) per share - basic (in Dollars per share)	$ 0	$ 0.01	$ 0	$ 0.01
Net income (loss) per share - diluted (in Dollars per share)	$ 0	$ 0.01	$ 0	$ 0.01
Weighted average shares outstanding - basic (in Shares)	20,000,000	20,000,000	20,000,000	20,000,000
Weighted average shares outstanding - diluted (in Shares)	20,000,000	20,000,000	20,000,000	20,000,000

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Mar. 31, 2021	$ 20,000	$ 21,307	$ (55,418)	$ (14,111)
Balance (in Shares) at Mar. 31, 2021	20,000,000
Imputed interest on related party loan		7,615		7,615
Proceeds from contributed capital		80,000		80,000
Net income (loss)			218,993	218,993
Balance at Dec. 31, 2021	$ 20,000	108,922	163,575	292,497
Balance (in Shares) at Dec. 31, 2021	20,000,000
Balance at Sep. 30, 2021	$ 20,000	89,019	(4,247)	104,772
Balance (in Shares) at Sep. 30, 2021	20,000,000
Imputed interest on related party loan		2,303		2,303
Proceeds from contributed capital		17,600		17,600
Net income (loss)			167,822	167,822
Balance at Dec. 31, 2021	$ 20,000	108,922	163,575	292,497
Balance (in Shares) at Dec. 31, 2021	20,000,000
Balance at Mar. 31, 2022	$ 20,000	111,291	116,553	$ 247,844
Balance (in Shares) at Mar. 31, 2022	20,000,000			20,000,000
Imputed interest on related party loan		7,671		$ 7,671
Proceeds from contributed capital				0
Net income (loss)			(18,850)	(18,850)
Balance at Dec. 31, 2022	$ 20,000	118,962	97,703	$ 236,665
Balance (in Shares) at Dec. 31, 2022	20,000,000			20,000,000
Balance at Sep. 30, 2022	$ 20,000	116,376	102,350	$ 238,726
Balance (in Shares) at Sep. 30, 2022	20,000,000
Imputed interest on related party loan		2,586		2,586
Net income (loss)			(4,647)	(4,647)
Balance at Dec. 31, 2022	$ 20,000	$ 118,962	$ 97,703	$ 236,665
Balance (in Shares) at Dec. 31, 2022	20,000,000			20,000,000

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ (4,647)	$ 167,822	$ (18,850)	$ 218,993
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Imputed interest on related party loan	2,586	2,303	7,671	7,615
Changes in assets and liabilities:
Deposits			0	(324,850)
Inventory			0	23,900
Accounts payable			96	0
Net cash provided by (used in) operating activities			(11,083)	(74,342)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from contributed capital		17,600	0	80,000
Proceeds from (repayments of) related party debt			10,829	(17,925)
Net cash provided by financing activities			10,829	62,075
Net decrease in cash and cash equivalents			(254)	(12,267)
Cash and cash equivalents at beginning of period			431	12,350
Cash and cash equivalents at end of period	$ 177	$ 83	177	83
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid			0	0
Income taxes paid			$ 0	$ 0

General Organization and Busine

General Organization and Business	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. General Organization and Business Rest EZ, Inc. (the “Company”) was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, at the present time the company is currently in full Production and Distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various Companies, but has not distributed this product to anyone except Rest EZ Inc. The Company’s year-end is March 31.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s financial statements for the year ended March 31, 2022 contained in the Company’s annual report on 10-K filed with the SEC on July 14, 2022. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosure of contingent liabilities in advance of all conditions being met at the date of the financial statements. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis. Revenue Recognition The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered. We adopted ASC Topic 606, “Revenue from Contracts with Customers”, and all related interpretations for recognition of our revenue. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied. There was no revenue during the nine months ended December 31, 2022; all revenue during the nine months ended December 31, 2021 was from product sales. Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $177 and $431 as of December 31, 2022 and March 31, 2022, respectively. There were no cash equivalents as of December 31, 2022 and March 31, 2022. The Federal Deposit Insurance Corporation (“FDIC”) insures these balances up to $250,000. At December 31, 2022 and March 31, 2022, cash in excess of the insured amount was $0. Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2022 and March 31, 2022. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

Going Concern

Going Concern	9 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2022, the Company had a net loss of $18,850. As of December 31, 2022, the Company had net working capital of $236,665 and retained earnings of $97,703. The Company has begun to recognize revenue, but without additional capital, the Company may not be able to remain in business. The continuation of the Company as a going concern is dependent upon (i) its ability to identify future investment opportunities, (ii) its ability to obtain any necessary debt and/or equity financing, which may include loans from related parties, and (iii) its ability to generate profits from the Company’s future operations. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Achievement of the Rest EZ, Inc.’s business objective is basically dependent upon the judgment, skill and knowledge of the Company’s management. Mr. Sosa is currently the Company’s sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death.

Deposits

Deposits	9 Months Ended
	Dec. 31, 2022
Disclosure Text Block Supplement [Abstract]
Other Assets Disclosure [Text Block]	Note 4. Deposits The Company deposits funds with its supplier in advance of inventory purchases. The amount of outstanding deposits at December 31, 2022 and March 31, 2022 was $405,000.

Inventory

Inventory	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 5. Inventory Inventory consists of one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider. At December 31, 2022 and March 31, 2022, inventory consisted of the following: December 31, 2022 March 31, 2022 Finished Goods Inventory $ 2,550 $ 2,550

Related Party Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 6. Related Party Transactions As of December 31, 2022 and March 31, 2022, Brandon Sosa, President and sole stockholder of the Company, had loaned the Company the amount of $129,279 and $118,450, respectively, for operating capital. During the nine months ended December 31, 2022 and 2021, the Company charged to operations the amount of $7,671 and $7,615, respectively, as imputed interest on these loans. During the nine months ended December 31, 2021, the Company’s founder and CEO sold 8,000,000 shares of common stock he personally owned to outside investors and contributed the proceeds in the amount of $80,000 to the Company. This amount is recorded as proceeds from contributed capital on the Company’s statement of changes in stockholder’s equity. See note 7.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 7. Stockholders Equity The Company has 100,000,000 authorized shares of common stock with $0.001 par value. As of December 31, 2022 and March 31, 2022, there were 20,000,000 shares of common stock outstanding. During the nine months ended December 31, 2021, Brandon Sosa, the Company’s founder and CEO, sold 8,000,000 shares of common stock he personally owned to outside investors at a price of $0.01 per share. See note 6. Proceeds in the net amount of $80,000 were contributed to the Company, and are recorded as contributed capital on the Company’s statement of stockholder’s equity (deficit) at December 31, 2021. Previous to this sale of shares, Mr. Sosa owned 20,000,000 shares of the Company’s common stock; subsequent to this sale of shares, Mr. Sosa owned 12,000,000 shares of the Company’s common stock. On October 17, 2016, the Company issued 20,000,000 shares of common stock to Brandon Sosa, the Company’s President, in exchange for $20,000. On May 26, 2021, the Company filed a Form S-1 with the Securities Exchange Commission in order to register the Company’s currently outstanding 20,000,000 shares of common stock. This registration statement became effective on July 19, 2021.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 8. Income Taxes There is no current or deferred income tax expense or benefit for the period ended December 31, 2022. The Company has not recognized an income tax expense or benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax expense for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. At December 31, 2022 and March 31, 2022, the Company had a net operating loss carryforward in the amount of $0.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 9. Subsequent Events The Company has evaluated events occurring subsequent to December 31, 2022 through the date these financial statements were issued and noted no items requiring disclosure.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s financial statements for the year ended March 31, 2022 contained in the Company’s annual report on 10-K filed with the SEC on July 14, 2022.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosure of contingent liabilities in advance of all conditions being met at the date of the financial statements. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis.
Revenue [Policy Text Block]	Revenue Recognition The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered. We adopted ASC Topic 606, “Revenue from Contracts with Customers”, and all related interpretations for recognition of our revenue. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied. There was no revenue during the nine months ended December 31, 2022; all revenue during the nine months ended December 31, 2021 was from product sales.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $177 and $431 as of December 31, 2022 and March 31, 2022, respectively. There were no cash equivalents as of December 31, 2022 and March 31, 2022. The Federal Deposit Insurance Corporation (“FDIC”) insures these balances up to $250,000. At December 31, 2022 and March 31, 2022, cash in excess of the insured amount was $0.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes
Commitments and Contingencies, Policy [Policy Text Block]	Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2022 and March 31, 2022.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider. At December 31, 2022 and March 31, 2022, inventory consisted of the following: December 31, 2022 March 31, 2022 Finished Goods Inventory $ 2,550 $ 2,550

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Accounting Policies [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 177	$ 431
Cash, FDIC Insured Amount	250,000
Cash, Uninsured Amount	$ 0

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (4,647)	$ 167,822	$ (18,850)	$ 218,993
Working Capital (Deficit)	236,665		236,665
Retained Earnings (Accumulated Deficit)	$ 97,703		$ 97,703		$ 116,553

Deposits (Details)

Deposits (Details) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Disclosure Text Block Supplement [Abstract]
Deposit Assets	$ 405,000	$ 405,000

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory, Current - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Schedule Of Inventory Current Abstract
Finished Goods Inventory	$ 2,550	$ 2,550

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Related Party Transactions (Details) [Line Items]
Imputed Interest	$ 2,586	$ 2,303	$ 7,671	$ 7,615
Sale of Stock, Number of Shares Issued in Transaction (in Shares)				8,000,000
Proceeds from Contributed Capital		$ 17,600	0	$ 80,000
President [Member]
Related Party Transactions (Details) [Line Items]
Proceeds from Related Party Debt			129,279		$ 118,450
Imputed Interest			$ 7,671	$ 7,615

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)		3 Months Ended	9 Months Ended
	Oct. 17, 2016	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Stockholders' Equity (Details) [Line Items]
Common Stock, Shares Authorized			100,000,000		100,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)			$ 0.001		$ 0.001
Common Stock, Shares, Outstanding			20,000,000		20,000,000
Sale of Stock, Number of Shares Issued in Transaction				8,000,000
Shares Issued, Price Per Share (in Dollars per share)		$ 0.01		$ 0.01
Proceeds from Contributed Capital (in Dollars)		$ 17,600	$ 0	$ 80,000
Investment Owned, Balance, Shares	20,000,000
Stock Issued During Period, Shares, New Issues	20,000,000
Stock Issued During Period, Value, New Issues (in Dollars)	$ 20,000
Chief Executive Officer [Member]
Stockholders' Equity (Details) [Line Items]
Investment Owned, Balance, Shares		12,000,000		12,000,000

Income Taxes (Details)

Income Taxes (Details)	Dec. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Operating Loss Carryforwards	$ 0